"The voice for cancer physicians and their patients in Massachusetts."

FDA Approved pembrolizumab (Keytruda) for the treatment of BCG-unresponsive

08 Jan 2020 2:47 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software